PATENT AI~TRACTS

ganisms to ship bottoms, to find chemicals toxic to marine fouling organisms and to permit rapid formulation of superior anti-fouling paints, using a bioluminescent microbiological assay. The bottoms of test vials are coated with a paint solution, the paint dried, and identical aliquots of an assay medium containing Pyrocystis lunula cells are added to the tests vials and to identical (but unpainted) control vials. After a preselected settling time, the vials are agitated and their light outputs measured and compared. Any dimuition of light in the test vials, relative to the control vials, in an indication of the anti-fouling charac- teristics of the paints being tested.

5192684

H U M A N I G G 1 M O N O C L O N A L A N T I B O D Y S P E C I F I C F O R T H E N I C O T I N I C A C E T Y L C H O L I N E R E C E P T O R A N D H Y B R I D O M A P R O D U C I N G T H E A N T I B O D Y

Masao Tauihara, Hideaki Yamada, Toshihide Nakashima, Yoshiaki Omura, Koichi Takakura, Espoo, assigned to Agency of Indus- trial Science & Technology; Ministry of Interna- tional Trade and Industry

A human IgGl type monoclonal antibody which possesses a molecular weight in the range of 180,000 +/-20,000 as measured by the method of polyaerylamide gel electrophoresis performed in the presence of sodium dodecyl sulfate and is specific to nicotinic acetyicholine receptor. The human IgGl type monoclonal antibody men- tioned above is produced by a method which comprises fusing human cells capable of pro- ducing an antibody against nicotinic ac- etylcholine receptor with propagable human cells thereby giving rise to a hybridoma capable of producing the aforementioned human IgG 1 type monoclonal antibody, selecting the hybridoma from the production of the fusion, culturing the hybridoma thereby giving rise to the aforementioned human IgG1 type mono- clonal antibody, and selecting the antibody from the cultured medium. The hybridoma mentioned above is also identified.

155

5192685

B I F I D O B A C T E R I U M S T R A I N S H A V I N G H I G H I G A I N D U C T I O N

P O T E N T I A L

Hisako Yasui, Kazuhito Hayakawa, Makoto Ohwaki, Tatsuhiko Kan, Espoo, assigned to Kabushiki Kaisha Yakult Honsha

The present invention is to provide an easy, rapid method for screening a great amount of substances having IgA induction potential. The IgA induction potential herein mentioned means the potential to activate and enhance the activity of IgA production cells to produce seeretory- type IgA in response to antigen. The present in- vention is to provide bacterial strains of genus Bifidobacterium obtained by the method for screening substances having IgA induction potential. More specifically, the present inven- tion is to provide Bifidohacterium longnm YIT 4062, Bifidohacterium breve YIT 4063 and Bi- fidobacterium breve YIT 4064. The three strains obtained by the present invention have high IgA induction potential.

5192690

P R O C E S S F O R T H E A N A L Y T I C A L D E T E R M I N A T I O N O F

A C E T Y L C Y A N A M I D E IN U R I N E

Ulrich Rust, Trostberg, Federal Republic Of Germany assigned to SKW Trostberg Ak- tiegesellschaft

The present invention is directed to a process for the analytical determination of acetyicyanamide in urine. It involves (a) the separating of ac- etylcyanamide at from a urine matrix and/or an extract which is obtained from a urine matrix by ion exchange chromatography or reverse phase high performance liquid chromatography (HPLC), and (b) detecting the acetylcyanamide at a wavelength of 220 nm. The matrix or the extract of it is cleaned by treatment with ac- tivated carbon at pH 7 to 13, and the ac- etylcyanamide may be extracted from the cleaned matrix or its extract at pH 0.5 to 3.5, e.g. by liquid-liquid extraction of the ac- etylcyanamide. This is carried out by means of water-insoluble, organic solvent such as ethyl ac- etate or diethyl ether.